• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

EC-Naprosyn (naproxen delayed-release tablets)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

March 2013

Summary View

WARNINGS

Renal Effects
  • Patients at greatest risk of this reaction are those taking………..or angiotensin receptor blockers (ARBs),
Advanced Renal Disease
  •  ...and patients should be adequately hydrated.